Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?

A greater understanding of anti-tumor immunity has resulted in rapid development of immunotherapy for a wide variety of cancers. Antibodies targeting the immune checkpoints, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-1 (PD-1), or its ligand (PD-L1) have demonstrated clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Chen, Rajan, Arun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788636/
https://www.ncbi.nlm.nih.gov/pubmed/31608320
http://dx.doi.org/10.21037/med.2019.08.02

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788636/
https://www.ncbi.nlm.nih.gov/pubmed/31608320
http://dx.doi.org/10.21037/med.2019.08.02

Ejemplares similares